| Name | Title | Contact Details |
|---|
Aminex Therapeutics, Inc. is focused on bringing its breakthrough discoveries to the clinic to improve the lives of cancer patients.
Libra Therapeutics is focused on developing novel disease-modifying therapeutics that can restore the cellular balance disrupted in neurodegenerative diseases.
Aspen is developing induced-pluripotent stem cells (iPSCs) to address diseases with high unmet medical need, beginning with autologous neuron replacement for both sporadic and genetic forms of Parkinson`s disease (PD) and extending across the brain and affected organs.
Learn why 2,000+ healthcare organizations and employers depend on our experts to improve patient outcomes with advanced diagnostics.
Oral integrin therapies for patients with immunological, fibrotic, neoplastic and vascular diseases. Morphic Tx is joining a three decade quest led by our scientific founder, Tim Springer, who initially discovered the integrin receptor family in the 1980s. This receptor family is an important drug target that has fueled the successful development of six injectable therapies approved for treatment of multiple sclerosis, ulcerative colitis, Crohn`s disease, plaque psoriasis, acute coronary syndrome and complications during percutaneous coronary intervention.